Encofosbuvir Application Scope

Indicated in combination with Netanasvir (Netanasvir Phosphate) capsules for the treatment of adult patients with chronic hepatitis C virus (HCV) infection of genotypes 1, 2, 3, or 6, including treatment-naïve patients and patients previously treated with interferon, with or without compensated cirrhosis.

Encofosbuvir Characteristics

Ingredients: Encofosbuvir
Properties: Oral, small-molecule NS5B inhibitor
Packaging Specification: 0.3 g tablet
Storage: Stored the powder at -20°C for three years; once dissolved in a solvent, it should be stored at -80°C for one year
Expiry Date: Shelf expiry period is provided on the product package insert
Executive Standard: The product was approved as a Class-1 innovative chemical drug in China
Approval Number: National Drug Approval No. H20250010
Date of Revision: Approved March 27, 2025
Manufacturer: Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd.

Guidelines for the Use of Encofosbuvir

Dosage and Administration:
- Recommended Dose: Encofosbuvir 0.3 g tablet, orally, once daily, administered in combination with Netanasvir (Netanasvir Phosphate) capsules according to the approved regimen. Refer to the official prescribing information for the exact Netanasvir dose and recommended treatment duration for each genotype and cirrhosis status.
- Administration: Oral administration. Take as directed by the prescriber. Use only in the specified combination regimen (Encofosbuvir + Netanasvir).
- Missed Dose: Specific missed-dose instructions are provided in the official package insert. If not available, patients should follow prescriber/pharmacist guidance; do not double dose to make up a missed dose.
Adverse Reactions:
- Common Adverse Reactions: Fatigue, headache, nausea, and other mild to moderate events consistent with NS5B/NS5A combination therapies.
- Serious Adverse Reactions: Serious adverse events (SAEs) have been infrequently reported in trial summaries; detailed SAE incidence, severity, and causality are described in the full prescribing information. No specific widespread, new safety signal publicly documented in the approval announcement. See full label for safety tables.
Contraindications:
- Known hypersensitivity to encofosbuvir or any excipient listed in the product label.
- Concomitant use with drugs that are explicitly contraindicated per the product label (see official prescribing information).
- The approval and public summary do not support use in decompensated cirrhosis or certain special populations unless label explicitly states otherwise—consult the label.
Precautions:
- Use only in combination with Netanasvir as per approved indication.
- Limited data in decompensated liver disease, severe renal impairment, pregnancy, and pediatrics—exercise caution and follow label recommendations.
- Monitor hepatic function and clinical status as clinically indicated. Refer to the official prescribing information for laboratory monitoring recommendations.

Encofosbuvir Interactions

The complete drug–drug interaction profile is described in the official prescribing information. Public approval summaries emphasize that Encofosbuvir is intended for use with Netanasvir; concomitant medications that may affect antiviral exposure or cause clinically relevant interactions should be evaluated per the label. For clinically important interactions and management guidance, consult the full product label before co-prescribing.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.